Highlights BioSenic SA

Equities

BIOS

BE0974280126

Market Closed - Euronext Bruxelles Other stock markets 11:22:18 2024-07-03 am EDT			5-day change	1st Jan Change
0.0151 ^EUR	-10.65%		-15.64%	-75.33%

Jul. 02	BioSenic, Phebra Update Licensing Terms for Oral Arsenic Trioxide Drug Development	MT
Jul. 02	BioSenic and Medsenic SAS Sign New Set of Licensing and Commercialization Agreements with Phebra Pty Ltd	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioSenic, Phebra Update Licensing Terms for Oral Arsenic Trioxide Drug Development	Jul. 02	MT
BioSenic and Medsenic SAS Sign New Set of Licensing and Commercialization Agreements with Phebra Pty Ltd	Jul. 02	CI
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...	Jun. 24
Belgium’s BioSenic Gets Court Approval for Debt Restructuring Plan	Jun. 14	MT
Biosenic: sufficient cash flow until the third quarter	Jun. 07	CF
Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2023	Jun. 05	CI
Biosenic: launch of a debt restructuring plan	Apr. 11	CF
Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease	Mar. 12	CI
BioSenic Unit Wins Canadian Patent for Therapeutic Platform	Jan. 30	MT
BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform	Jan. 30	CI
BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress	Jan. 25	CI
BioSenic Files US Patent for Osteoarthritis Therapy	Jan. 23	MT
BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA	Jan. 23	CI
Biosenic: partnership with Phebra PTY evolves	Jan. 15	CF
BioSenic Signs Binding Term Sheet with Phebra for Oral Formulation Development of cGvHD Treatment	Jan. 15	MT
BioSenic Reaches Agreement on A Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment	Jan. 15	CI
BioSenic S.A. Performs Further Analysis of Its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide in cGvHD	23-09-27	CI
BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Treatment Supporting Clinical Trial for Systemic Sclerosis	23-09-19	CI
BioSenic Secures Patent in China for Arsenic Trioxide Platform	23-08-24	MT
BioSenic S.A. Puts Phase IIb Allob Trial on Hold	23-06-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioSenic SA

Equities

BIOS

BE0974280126

Highlights

Filters